How Long Do Dermal Fillers Last? A Guide by Filler Type and Area

Dermal fillers last anywhere from four months to more than two years, and the number a patient finds online is usually the best case for a product that may not be the one they are being treated with. The honest range for hyaluronic acid fillers is six to eighteen months, depending on the product, the area and the patient; calcium hydroxylapatite typically runs twelve to eighteen months; poly-L-lactic acid builds over three to four months and holds for eighteen to twenty-four; and PDRN or polynucleotide boosters are not volumetric fillers at all, so their three-to-six-month window measures skin quality rather than projection.

That spread is not marketing noise. It comes from four independent variables that compound: the chemistry of the gel, the mechanics of the treatment area, the way an individual patient breaks the product down, and the technique used to place it. Change any one of them and the same syringe behaves differently.

Most patient confusion comes from a single mistaken model — that filler is a substance sitting in the face until it is used up. In reality injectable hyaluronic acid fillers are gels that bind water, deform under movement, and are gradually broken down by enzymatic and mechanical processes while the surrounding tissue responds to their presence. What a patient sees at month nine is a combination of residual gel, residual water binding, and whatever collagen response the product provoked.

That matters for anyone advising patients, because the question "how long will it last" is really three questions wearing one coat: how long will the volume stay, how long will the aesthetic effect stay, and how long will the patient believe it is still there. They do not expire on the same date.

This guide sets out typical duration by filler type and by treatment area, explains what actually drives the differences, and covers the maintenance decisions that determine whether a patient looks consistent over five years or cycles through over-correction and waiting. It is written for clinics and distributors working in the US market, and for the patient questions those teams field every week.

Every number below is a typical range from published product information and clinical experience, not a guarantee. Individual results vary with anatomy, metabolism and aftercare, and any treatment decision belongs with a qualified clinician who has assessed the specific patient.

How Long Do Dermal Fillers Last? The Range at a Glance

Four families dominate the market, and they do not age the same way. Hyaluronic acid products are true gels that occupy space and are reabsorbed. Calcium hydroxylapatite and poly-L-lactic acid are biostimulators: the carrier is absorbed relatively quickly and the visible result is largely new collagen laid down in response, which is why their effect can outlast the material itself. PDRN and polynucleotide products sit in a different category again — they are regenerative boosters rather than volumizers.

Two practical warnings about that table. First, the upper end of each range belongs to a patient with thick tissue, low movement in the area, and a product formulated for longevity — not to a typical first-time patient. Second, quoted durations usually describe visible correction, which ends earlier than the material does. Imaging studies routinely find HA still present months after a clinician would call the result settled.

The gap between "visible" and "present" is why patient expectation management is mostly a matter of language. A patient told eight to twelve months for a cheek product will not be alarmed at month ten; a patient told "a year to eighteen months" will.

Why the Same Filler Lasts Different Lengths in Different Faces

Anatomy sets the clock more than the syringe does. Three properties of a treatment area determine how quickly a product is cleared: how vascular the tissue is, how much it moves, and how thick the overlying soft tissue is. Areas with high vascularity and constant movement clear product fastest; areas with thick, relatively static tissue hold it longest.

Vascularity matters because breakdown products are carried away by blood flow. Movement matters because repeated deformation mechanically fragments the gel and disperses it. Tissue thickness matters because thin skin offers less physical confinement, so product in the tear trough or on the lip border spreads and flattens sooner than product placed on the periosteum of the cheek.

Lips: short because they are busy

Lips move more than any other treatable area — speech, eating, expression, and for many patients a lifetime of unconscious pursing. They are also highly vascular and covered by mucosa rather than thick dermis. Typical HA duration in the lips is six to nine months, and a patient who talks for a living or plays a wind instrument will often sit at the short end.

The failure mode here is over-treating to compensate. Because lips lose volume visibly and quickly, there is a temptation to use a firmer, longer-lasting product than the tissue tolerates. High-G′ gel in a mobile lip tends to produce palpable lumps and a stiff, unnatural border rather than longevity.

Tear troughs: thin skin, high stakes

The periorbital area combines thin skin, constant movement from blinking and expression, and a lymphatic system that clears fluid efficiently. HA here typically holds nine to twelve months — often less in patients with strong allergic rhinitis or chronic eye rubbing.

This is the area where product choice matters most and where a "longer-lasting" product is often the wrong answer. Firm gels placed superficially under thin skin produce a bluish Tyndall effect or visible ridges that persist longer than the correction would have. A softer, lower-G′ product that lasts eight months and looks clean is a better clinical outcome than a twelve-month product that looks wrong for six of them.

Cheeks and midface: the longest HA window

Cheek augmentation places product deep, often on or near the periosteum, through thick soft tissue with relatively little shear. This is where HA reaches twelve to eighteen months, and where the difference between a well-placed deep bolus and a superficially placed product is most visible over time.

Movement still matters — smiling displaces midface tissue — but the deep plane distributes that force across a broader area rather than fragmenting the gel.

Jawline and chin: structural, and it shows

Jawline and chin work is structural and sits in a region with thick tissue and strong but directional movement. HA typically lasts twelve to eighteen months. The common misjudgement is assuming the jawline holds filler like the cheek; the mandibular border is under repeated shear from talking and clenching, and patients who brux often report earlier softening.

Temples: quiet area, long hold

The temple is one of the quietest treatable areas — thin muscle activity, deep placement, good tissue support. HA at twelve to eighteen months is realistic, and the area often looks unchanged for longer than the patient expects simply because hollowing is gradual.

Hands: thin, mobile, and unforgiving

Hands have very thin skin over tendon and bone, constant movement, and high sun exposure. HA gives six to twelve months; hyperdilute CaHA is often used specifically because its low-viscosity dispersion and collagen stimulation suit the area better than a bolus of gel. Patients rarely notice hand correction fading until it is largely gone, so rebooking conversations have to be proactive.

These ranges shift with the product family, not just the area. The area-by-area selection logic — which gel consistency belongs where, and why the same product is right for a cheek and wrong for a lip — is set out in choosing a dermal filler by facial area.

What Actually Determines How Long a Filler Lasts

Nine variables carry most of the variance. Clinics tend to discuss the first two and ignore the rest, which is why patients are surprised when their result behaves differently from a friend's.

Cross-linking density

Hyaluronic acid in its native form is cleared within days. Cross-linking the polymer chains — most commonly with BDDE — creates a network that resists enzymatic breakdown and mechanical dispersion. Higher BDDE cross-linking density buys duration, but it also produces a stiffer gel, more swelling during the first days, and a product that is harder to place finely. Duration is not free.

Elastic modulus (G′) and cohesivity

G′ describes how firmly a gel returns to shape after deformation. A high-G′ product resists the shear of a moving cheek and holds projection; a low-G′ product spreads softly and suits thin, mobile tissue. Cohesivity — how well the gel holds together — determines whether it stays where it was placed under repeated load. A cohesive gel in a high-movement area outperforms a stiffer but less cohesive one.

HA concentration and water binding

Most dermal fillers sit in the 20–24 mg/mL range. Concentration affects swelling and lift more than it affects longevity, which is a common commercial misreading: a 24 mg/mL product is not automatically longer-lasting than a 20 mg/mL one if its cross-linking is lower. Water binding is what produces the immediate plumping effect, and it declines before the gel itself is gone.

Particle structure: monophasic versus biphasic

Biphasic products suspend particles in a carrier gel; monophasic products are a single continuous phase. Monophasic and biphasic gels differ in how they fragment under load and therefore in how they age in a moving area — not simply in how long they last.

Injection plane and technique

Deep placement on periosteum confines the product, reduces dispersion, and extends duration. Superficial placement in thin skin spreads the same volume over a larger footprint, so it looks fuller immediately and fades faster. This is the single largest technique variable, and the one least visible in a product brochure.

Metabolism and individual clearance

Patients differ by a factor that no product can control: how quickly they break down exogenous HA. Younger patients with high metabolic turnover, athletes, and patients with autoimmune or inflammatory conditions often clear product faster. So do patients who have had repeated treatments in the same area, because a fibrous capsule can form and change how subsequent product behaves.

Weight change

Significant weight loss reduces facial fat and thins the soft-tissue envelope around the filler. The product is still there, but the face around it has changed, so the correction looks different or appears to have "moved". Clinicians see this most often after rapid loss of 5 kg or more, and it is frequently misattributed to product migration.

Exercise, heat and sun

Regular high-intensity exercise, sauna use and significant sun exposure are associated with faster apparent fading. The mechanisms are indirect — increased blood flow and free-radical load accelerate polymer breakdown — but the clinical pattern is consistent enough that it belongs in the consent conversation.

Smoking and lifestyle

Smoking impairs microcirculation and increases oxidative stress, which is why smokers often report shorter duration and more uneven results. This is not a reason to refuse treatment, but it is a reason to set expectations lower and to document the advice.

Additives such as lidocaine

Lidocaine is added for comfort and does not meaningfully change how long the gel lasts — but it does change the treatment experience and the early swelling profile, which patients often conflate with durability. The practical differences between lidocaine-containing and plain HA fillers are worth explaining before a patient assumes the numb version is the weaker one.

What "Lasting" Actually Means

Duration claims are only meaningful once you specify which endpoint is being measured. Three different endpoints are routinely mixed together.

Material presence is the longest: HA remains detectable on imaging well after the aesthetic result has settled, and PLLA particles persist for months while collagen matures around them.

Visible volume is shorter. Water binding accounts for a meaningful share of the immediate lift, and as the gel fragments it binds less water even while material remains. A patient at month eight may still have product in the area and no longer have the projection they paid for.

Patient-perceived effect is the shortest and the most variable. It is anchored to a photograph, a comment from a partner, or how clothes fit — none of which track the material. Patients who see themselves daily adapt to the change and register "it is gone" earlier than a clinician would.

Biostimulators complicate the picture further. With PLLA, the visible result is new collagen, so the effect can persist after the particles are fully resorbed — which is why a product can honestly claim eighteen to twenty-four months while the material itself is gone in less than that. The reverse error also happens: clinics explain PLLA as if it were a gel that dissolves, and patients are confused when it keeps improving after they were told to expect fading.

The practical fix is to name the endpoint in the consultation: "the projection will soften around month ten, and the skin quality improvement will be the last thing you notice" is a sentence that prevents a dozen questions later.

Maintenance: Little and Often, or Fewer Larger Sessions?

Once duration is understood as a range rather than a deadline, maintenance becomes a scheduling decision rather than an emergency. Two strategies dominate, and they produce visibly different faces after three years.

Small, frequent top-ups keep volume within a narrow band. The patient never looks overfilled and never looks deflated, but they attend more often and the cumulative cost is higher.

Fewer, larger sessions reduce visits and cost per year, at the price of a visible cycle: a full result for several months, then a noticeable decline. Patients who photograph themselves regularly find this cycle harder than the cost.

Timing should be driven by tissue behaviour, not the calendar. The useful question is not "is it time?" but "has the area lost the support it had at the review appointment?" — judged against the baseline photographs, not memory.

The cost trap deserves its own line, because it is where duration claims are most often used badly. A clinic comparing syringes by price alone will pick the cheaper product and treat twice as often. The relevant number is cost per month of correction, and it flips the ranking: an illustrative $300 product lasting six months costs about $50 a month, while a $600 product lasting eighteen costs about $33 — before counting the extra appointments, travel and time off work.

For Clinics and Distributors: Reading Duration as Product Positioning

Duration is not only a clinical property; it is the axis most aesthetic brands actually compete on, and it determines how a product should be stocked and sold.

Short-duration products suit event-driven demand — weddings, campaigns, seasonal work — where patients want correction now and are comfortable returning. They carry lower unit cost and higher visit frequency.

Long-duration and biostimulator products suit patients who want to stop thinking about their face between visits, and they justify a premium price because the cost per month is lower even when the sticker price is higher.

For a distributor, the portfolio question is coverage rather than preference: a range built entirely on short-duration HA will lose the patient who asks for something that lasts, and a range built entirely on long-duration biostimulators will lose the patient who wants reversibility. The calcium hydroxylapatite category is the usual bridge, because it sits between HA and PLLA on both duration and reversibility.

Two sourcing details follow from that. First, confirm what the manufacturer's stated duration actually measures — material, visible correction, or collagen response — because the numbers are not comparable across categories. Second, check that the documentation supports the claim for the dilution and plane you intend to use, since hyperdilute use can change the endpoint entirely.

Which Fillers Last Longest — and Which Last Long Enough

Ranked by duration alone, PLLA sits at the top with eighteen to twenty-four months, CaHA follows at twelve to eighteen, and HA spans the widest range because it is the most tunable family. PDRN and polynucleotide boosters are not in that ranking: they improve skin quality over three to six months and should not be sold as a substitute for volume.

The more useful question for a clinic is not which product lasts longest but which product's duration matches the patient's tolerance for maintenance. A patient who will not return for a year is better served by a biostimulator than by a short-duration gel, even if the gel is the better product on paper.

That is also where the regenerative category earns its place. PDRN for skin quality works on texture and hydration on a shorter cycle, and it is often used between volumetric sessions rather than instead of them.

For products that build rather than fill, the timeline is the point: PLLA-PEG formulations are judged at three months, not three weeks, and a clinic that reviews them too early will over-treat. The same logic applies to Sculptra's PLLA particles, where the visible result at month one is a fraction of what the patient will see at month four.

For HA, the practical rule is that duration should be matched to the area before it is matched to the price list. A long-lasting gel in the lips is not a better purchase; it is a worse outcome that happens to last.

Conclusion: Set the Expectation, Then Beat It

Dermal fillers last six to eighteen months in most HA applications, twelve to eighteen for CaHA, eighteen to twenty-four for PLLA, and three to six months for PDRN and polynucleotide boosters measured on skin quality rather than volume. Within each category, the area and the patient decide where in the range a result lands.

The clinics that manage this well do three things: they quote a range with the area attached, they distinguish volume from effect when they explain what will fade, and they schedule maintenance against photographs rather than the calendar. None of that requires a longer-lasting product — it requires a clearer conversation.

AOWITA supplies cross-linked hyaluronic acid fillers and regenerative formulations for clinics, distributors and private-label brands, with the batch documentation and technical information professional buyers need to match a product to an area and a patient population. Explore the cross-linked HA dermal filler range, or contact the team for specifications, dilution guidance and sample requests.